ENTA—Just create and multiply the previous success model over and over.
If it were that easy, biotech investing too would be easy. In truth, there’s a good measure of luck to being in the right place at the right time, as ENTA was when it inked the HCV collaboration with Abbott in 2006 (#msg-15492225).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”